PURPOSE: Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients of 83% and 58%, respectively. We report clinical outcomes with axi-cel in the standard-of-care (SOC) setting for the approved indication. PATIENTS AND METHODS: Data were collected retrospectively from all patients with relapsed/refractory LBCL who underwent leukapheresis as of September 30, 2018, at 17 US institutions with the intent to receive SOC axi-cel. Toxicities were graded and managed according to each institution's guidelines. Responses were assessed as per Lugano 2014 classification. RESULTS: Of 298 patients who underwent leukapheresis, 275 (92%) received axi-cel therapy. Compared with the registrational ZUMA-1 trial, 129 patients (43%) in this SOC study would not have met ZUMA-1 eligibility criteria because of comorbidities at the time of leukapheresis. Among the axi-cel-treated patients, grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 7% and 31%, respectively. Nonrelapse mortality was 4.4%. Best overall and complete response rates in infused patients were 82% (95% CI, 77% to 86%) and 64% (95% CI, 58% to 69%), respectively. At a median follow-up of 12.9 months from the time of CAR T-cell infusion, median progression-free survival was 8.3 months (95% CI, 6.0 to15.1 months), and median overall survival was not reached. Patients with poor Eastern Cooperative Oncology Group performance status of 2-4 and elevated lactate dehydrogenase had shorter progression-free and overall survival on univariable and multivariable analysis. CONCLUSION: The safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.
PURPOSE: Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients of 83% and 58%, respectively. We report clinical outcomes with axi-cel in the standard-of-care (SOC) setting for the approved indication. PATIENTS AND METHODS: Data were collected retrospectively from all patients with relapsed/refractory LBCL who underwent leukapheresis as of September 30, 2018, at 17 US institutions with the intent to receive SOC axi-cel. Toxicities were graded and managed according to each institution's guidelines. Responses were assessed as per Lugano 2014 classification. RESULTS: Of 298 patients who underwent leukapheresis, 275 (92%) received axi-cel therapy. Compared with the registrational ZUMA-1 trial, 129 patients (43%) in this SOC study would not have met ZUMA-1 eligibility criteria because of comorbidities at the time of leukapheresis. Among the axi-cel-treated patients, grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 7% and 31%, respectively. Nonrelapse mortality was 4.4%. Best overall and complete response rates in infused patients were 82% (95% CI, 77% to 86%) and 64% (95% CI, 58% to 69%), respectively. At a median follow-up of 12.9 months from the time of CAR T-cell infusion, median progression-free survival was 8.3 months (95% CI, 6.0 to15.1 months), and median overall survival was not reached. Patients with poor Eastern Cooperative Oncology Group performance status of 2-4 and elevated lactate dehydrogenase had shorter progression-free and overall survival on univariable and multivariable analysis. CONCLUSION: The safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.
Authors: Hamza Hashmi; Christina Bachmeier; Julio C Chavez; Jinming Song; Mohammad Hussaini; Gabriel Krivenko; Taiga Nishihori; Hiroshi Kotani; Marco L Davila; Frederick L Locke; Michael D Jain Journal: Br J Haematol Date: 2019-08-13 Impact factor: 6.998
Authors: Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu Journal: Lancet Oncol Date: 2018-12-02 Impact factor: 41.316
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Laurie H Sehn; Brian Berry; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Paul Hoskins; Richard Klasa; Kerry J Savage; Tamara Shenkier; Judy Sutherland; Randy D Gascoyne; Joseph M Connors Journal: Blood Date: 2006-11-14 Impact factor: 22.113
Authors: Michael R Bishop; Richard T Maziarz; Edmund K Waller; Ulrich Jäger; Jason R Westin; Joseph P McGuirk; Isabelle Fleury; Harald Holte; Peter Borchmann; Christopher Del Corral; Ranjan Tiwari; Özlem Anak; Rakesh Awasthi; Lida Pacaud; Vadim V Romanov; Stephen J Schuster Journal: Blood Adv Date: 2019-07-23
Authors: Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall Journal: Blood Date: 2014-05-29 Impact factor: 22.113
Authors: Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu Journal: Biol Blood Marrow Transplant Date: 2018-12-25 Impact factor: 5.742
Authors: Peter Dreger; Sascha Dietrich; Maria-Luisa Schubert; Lorenz Selberg; Andrea Bondong; Mandy Wegner; Peter Stadtherr; Christoph Kimmich; Florentina Kosely; Anita Schmitt; Petra Pavel; Nora Liebers; Thomas Luft; Ute Hegenbart; Aleksandar Radujkovic; Anthony Dick Ho; Carsten Müller-Tidow; Michael Schmitt Journal: Blood Adv Date: 2020-12-22
Authors: Frederick L Locke; John M Rossi; Sattva S Neelapu; Caron A Jacobson; David B Miklos; Armin Ghobadi; Olalekan O Oluwole; Patrick M Reagan; Lazaros J Lekakis; Yi Lin; Marika Sherman; Marc Better; William Y Go; Jeffrey S Wiezorek; Allen Xue; Adrian Bot Journal: Blood Adv Date: 2020-10-13
Authors: Jay Y Spiegel; Saurabh Dahiya; Michael D Jain; John Tamaresis; Loretta J Nastoupil; Miriam T Jacobs; Armin Ghobadi; Yi Lin; Matthew Lunning; Lazaros Lekakis; Patrick Reagan; Olalekan Oluwole; Joseph McGuirk; Abhinav Deol; Andre Goy; Khoan Vu; Charalambos Andreadis; Javier Munoz; N Nora Bennani; Julie M Vose; Kathleen A Dorritie; Sattva S Neelapu; Frederick L Locke; Aaron P Rapoport; Brian T Hill; David B Miklos Journal: Blood Date: 2021-04-01 Impact factor: 22.113
Authors: Chelsea C Pinnix; Jillian R Gunther; Bouthaina S Dabaja; Paolo Strati; Penny Fang; Misha C Hawkins; Sherry Adkins; Jason Westin; Sairah Ahmed; Luis Fayad; Hun Ju Lee; Ranjit Nair; Raphael E Steiner; Swaminathan P Iyer; M Alma Rodriguez; Michael Wang; Christopher Flowers; Sattva S Neelapu; Loretta J Nastoupil Journal: Blood Adv Date: 2020-07-14
Authors: Cristina Gutierrez; Anne Rain T Brown; Heather P May; Amer Beitinjaneh; R Scott Stephens; Prabalini Rajendram; Joseph L Nates; Stephen M Pastores; Ananda Dharshan; Alice Gallo de Moraes; Matthew K Hensley; Lei Feng; Jennifer N Brudno; Janhavi Athale; Monalisa Ghosh; James N Kochenderfer; Alejandro S Arias; Yi Lin; Colleen McEvoy; Elena Mead; Jason Westin; Natalie Kostelecky; Agrima Mian; Megan M Herr Journal: Crit Care Med Date: 2022-01-01 Impact factor: 7.598